ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

01 Aug 2024 16:00:00 By Nasdaq GlobeNewswire

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

29 Jul 2024 07:35:00 By Nasdaq GlobeNewswire

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

29 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

23 Jul 2024 08:00:01 By Nasdaq GlobeNewswire

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

22 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

09 Jul 2024 16:53:01 By Nasdaq GlobeNewswire

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

09 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jul 2024 16:00:00 By Nasdaq GlobeNewswire

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

10 Jun 2024 14:30:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jun 2024 16:00:00 By Nasdaq GlobeNewswire

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

03 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

14 May 2024 16:00:00 By Nasdaq GlobeNewswire

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

13 May 2024 08:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 May 2024 16:00:00 By Nasdaq GlobeNewswire

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

29 Apr 2024 16:00:00 By Nasdaq GlobeNewswire

Arcutis Appoints David Topper as Chief Financial Officer

10 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Apr 2024 16:00:00 By Nasdaq GlobeNewswire

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

28 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

11 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

10 Mar 2024 16:00:00 By Nasdaq GlobeNewswire